We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Hutchmed (China) Ltd on Friday said it will receive a milestone payment from Takeda Pharmaceutical Co Ltd after Taked ...
Takeda Pharmaceutical Co Ltd on Thursday raised full year forecasts to reflect a stronger than anticipated first-half ...
Takeda Pharmaceutical Co Ltd on Tuesday said it landed an approval for its Fruzaqla drug in Japan. The drug has bee ...
Ltd - Hong Kong-headquartered biopharmaceutical company - Notes that Takeda Pharmaceuticals Co Ltd received a notifica ...
Takeda Pharmaceutical Co Ltd on Thursday said annual revenue increased, though profit plummeted on increased expenses ...
Takeda Pharmaceutical Co Ltd, Astellas Pharma Inc and Sumitomo Mitsui Financial Group Inc on Monday agreed to establi ...
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire DUBAI, UAE, March 27, 2024 Takeda's 'In Their Shoes' initiative illuminates the daily...
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire DUBAI, UAE, March 27, 2024 Takeda's 'In Their Shoes' initiative illuminates the daily...
Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has receive ...
Takeda Pharmaceutical Co Ltd on Monday said profit fell in the first half of its financial year, despite revenue risi ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 49.35 | 49.35 | 49.35 | 0 | 0 | DE |
4 | 0 | 0 | 49.35 | 49.35 | 49.35 | 0 | 0 | DE |
12 | 0 | 0 | 49.35 | 49.35 | 49.35 | 0 | 0 | DE |
26 | 0 | 0 | 49.35 | 49.35 | 49.35 | 0 | 0 | DE |
52 | 0 | 0 | 49.35 | 49.35 | 49.35 | 0 | 0 | DE |
156 | 0 | 0 | 49.35 | 49.35 | 49.35 | 0 | 0 | DE |
260 | 0 | 0 | 49.35 | 49.35 | 49.35 | 1 | 49.35 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions